000			01482 a2200409 4500
005			20250516055004.0
264		0	_c20120731
008			201207s 0 0 eng d
022			_a1573-2584
024	7		_a10.1007/s11255-011-0051-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aDutkiewicz, Slawomir A
245	0	0	_aComparison of maximal and more maximal intermittent androgen blockade during 5-year treatment of advanced prostate cancer T3NxMx-1. _h[electronic resource]
260			_bInternational urology and nephrology _cApr 2012
300			_a487-92 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAndrogen Antagonists _xadministration & dosage
650	0	4	_aBiopsy
650	0	4	_aDisease Progression
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aEndosonography
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aProspective Studies
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Neoplasms _xblood
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
773	0		_tInternational urology and nephrology _gvol. 44 _gno. 2 _gp. 487-92
856	4	0	_uhttps://doi.org/10.1007/s11255-011-0051-6 _zAvailable from publisher's website
999			_c21170467 _d21170467